Can enhancement be distinguished from prevention in genetic medicine?

The Journal of Medicine and Philosophy
E T Juengst

Abstract

In discussions of the ethics of human gene therapy, it has become standard to draw a distinction between the use of human gene transfer techniques to treat health problems and their use to enhance or improve normal human traits. Some dispute the normative force of this distinction by arguing that it is undercut by the legitimate medical use of human gene transfer techniques to prevent disease-such as genetic engineering to bolster immune function, improve the efficiency of DNA repair, or add cellular receptors to capture and process cholesterol. If disease prevention is a proper goal of medicine, these critics argue, and the use of gene transfer techniques to enhance human health maintenance capacities will help achieve that goal, then the "treatment/enhancement" distinction cannot define the limits of legitimate gene therapy. In this paper, I argue that a line can be drawn between prevention and enhancement for gene therapy (and thus between properly medical and nonmedical uses of gene therapy), but only if one is willing to accept two rather old-fashioned claims: 1) Some health problems are best understood as if they were entities in their own right, reifiable as processes or parts in a biological system, with at least as muc...Continue Reading

Citations

Sep 18, 2012·Health Care Analysis : HCA : Journal of Health Philosophy and Policy·Lisa S Parker
Sep 1, 2005·Journal of Medical Ethics·I de Melo-Martín
Jun 8, 1999·Lancet·P R BillingsS A Newman
Apr 9, 2005·Bioethics·Peter Wenz
Sep 17, 2003·Journal of Intellectual Disability Research : JIDR·H P Meininger
Dec 17, 2008·Biotechnology Journal·Jens Clausen
Jan 1, 2010·Human Reproduction and Genetic Ethics·Michael Fuchs
Jul 31, 2016·The Journal of Medicine and Philosophy·John Skalko, Mark J Cherry
Mar 25, 1999·Cadernos de saúde pública·D Neri
Aug 4, 2001·Human Gene Therapy·D B Resnik, P J Langer
Feb 15, 2001·Human Gene Therapy·J L Scully, C Rehmann-Sutter
Feb 3, 2007·Southern Medical Journal·James F Keenan
Aug 8, 2020·The American Journal of Bioethics : AJOB·Bryan Cwik
Nov 7, 2000·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·J R Botkin
Aug 8, 2020·The American Journal of Bioethics : AJOB·John H Evans
Jan 30, 2019·Annual Review of Medicine·Barry S Coller
Sep 19, 2019·Cambridge Quarterly of Healthcare Ethics : CQ : the International Journal of Healthcare Ethics Committees·Bryan Cwik
Feb 23, 2018·Medicine, Health Care, and Philosophy·David A Jensen
Feb 1, 2017·The Journal of Consumer Research·Detelina MarinovaJ B Silvers
Oct 13, 2020·Medicine, Health Care, and Philosophy·Nikolai MünchNorbert W Paul
Apr 11, 2021·Medicine, Health Care, and Philosophy·Jon RuedaFrancisco Lara
May 30, 2021·Proceedings of the National Academy of Sciences of the United States of America·John H Evans

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Literature and Medicine
J J Hughes, J Lantos
Journal of Pediatric Gastroenterology and Nutrition
F D Ledley
Mental Retardation and Developmental Disabilities Research Reviews
John C Fletcher
© 2021 Meta ULC. All rights reserved